Key Points
- Chidozie Ugwumba, a major shareholder, sold multiple blocks of Clene stock in December — including 3,350 shares on Dec. 26 at $6.32 and a 56,577-share sale on Dec. 3 at $7.86 — and after the latest sale still owns 795,824 shares (~$5.03M), a 0.42% reduction in his position.
- Clene is a clinical-stage biopharmaceutical with negative earnings (last quarter EPS -$0.85) and a market cap of about $61.6M; analysts have a consensus rating of Moderate Buy with a consensus price target of $32.60 despite a 12-month trading range of $2.28–$13.50.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 3,350 shares of the firm's stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $6.32, for a total transaction of $21,172.00. Following the completion of the sale, the insider owned 795,824 shares in the company, valued at $5,029,607.68. The trade was a 0.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $42,830.37.
- On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $9,342.30.
- On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total value of $28,560.18.
- On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The shares were sold at an average price of $6.45, for a total value of $36,003.90.
- On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
- On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total value of $36,815.28.
- On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total transaction of $19,063.24.
- On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total transaction of $44,359.30.
- On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
- On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The stock was sold at an average price of $6.79, for a total transaction of $51,624.37.
Clene Price Performance
Clene stock opened at $5.96 on Wednesday. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The stock has a market capitalization of $61.57 million, a PE ratio of -1.76 and a beta of 0.79. The firm has a 50 day simple moving average of $8.20 and a 200-day simple moving average of $6.34.
Clene (NASDAQ:CLNN - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.06 million. On average, analysts forecast that Clene Inc. will post -5.19 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a research report on Tuesday, October 14th. D. Boral Capital reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Clene in a research note on Wednesday, December 10th. Benchmark reissued a "buy" rating on shares of Clene in a research note on Thursday, December 4th. Finally, UBS Group restated a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $32.60.
Get Our Latest Research Report on CLNN
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp acquired a new stake in shares of Clene during the third quarter valued at approximately $29,000. Jane Street Group LLC acquired a new position in Clene in the 2nd quarter worth approximately $47,000. Lunt Capital Management Inc. grew its position in Clene by 71.2% during the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock worth $199,000 after purchasing an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP raised its stake in Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company's stock valued at $558,000 after purchasing an additional 42,750 shares during the period. 23.28% of the stock is owned by hedge funds and other institutional investors.
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
